GlassScriptPhysician profile
Charles P Stewart, III
NPI 1629072210
$3,550.80
in general payments reported to CMS, 2019-2025
24 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $190 · 2021: $844 · 2022: $711 · 2023: $661 · 2024: $319 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416 · Education: $12.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.55 |
| Education | $12.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,176.33 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $651.69 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $454.49 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $271.28 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $147.63 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $137.04 | 2025 | Rezdiffra |
| Genzyme Corporation | $132.89 | 2022-2025 | |
| Pfizer INC. | $98.42 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $61.94 | 2022-2024 | Dupixent |
| Allergan, INC. | $49.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.92 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $41.89 | 2021-2023 | |
| Ardelyx, INC. | $40.68 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $34.92 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $33.90 | 2022-2023 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $30.01 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $26.58 | 2019-2022 | |
| Biocon Biologics INC | $21.57 | 2025 | Yesintek |
| Sandoz INC. | $20.05 | 2023 | Hyrimoz |
| Medtronic, INC. | $18.35 | 2021 | |
| Vivus LLC | $17.68 | 2021 | |
| Boston Scientific Corporation | $15.22 | 2020 | |
| Organon LLC | $14.54 | 2025 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.